Literature DB >> 29253516

Inducible overexpression of endothelial proNGF as a mouse model to study microvascular dysfunction.

Riyaz Mohamed1, Maha Coucha1, Sally L Elshaer1, Sandeep Artham1, Tahira Lemtalsi1, Azza B El-Remessy2.   

Abstract

Impaired maturation of nerve growth factor precursor (proNGF) and its accumulation has been reported in several neurodegenerative diseases, myocardial infarction and diabetes. To elucidate the direct impact of proNGF accumulation identified the need to create a transgenic model that can express fully mutated cleavage-resistant proNGF. Using Cre-Lox technology, we developed an inducible endothelial-specific proNGF transgenic mouse (proNGFLoxp) that overexpresses GFP-conjugated cleavage-resistant proNGF123 when crossed with VE-cadherin-CreERT2 (Cre). Expression of proNGF, inflammatory mediators, NGF and VEGF was evaluated by PCR, Western blot and immunohistochemistry. EC-proNGF overexpression was confirmed using colocalization of anti-proNGF within retinal vasculature. EC-proNGF did not cause retinal neurotoxicity or marked glial activation at 4-weeks. Microvascular preparation from Cre-proNGF mice showed significant imbalance of proNGF/NGF ratio, enhanced expression of TNF-α and p75NTR, and tendency to impair TrkA phosphorylation compared to controls. EC-proNGF overexpression triggered mRNA expression of p75NTR and inflammatory mediators in both retina and renal cortex compared to controls. EC-proNGF expression induced vascular permeability including breakdown of BRB and albuminuria in the kidney without affecting VEGF level at 4-weeks. Histopathological changes were assessed after 8-weeks and the results showed that EC-proNGF triggered formation of occluded (acellular) capillaries, hall mark of retinal ischemia. EC-proNGF resulted in glomerular enlargement and kidney fibrosis, hall mark of renal dysfunction. We have successfully created an inducible mouse model that can dissect the contribution of autocrine direct action of cleavage-resistant proNGF on systemic microvascular abnormalities in both retina and kidney, major targets for microvascular complication.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acellular capillary; Apoptosis; Barrier dysfunction; Diabetic retinopathy; Inflammation; Nerve growth factor; Neurodegeneration; Neurotrophin

Mesh:

Substances:

Year:  2017        PMID: 29253516      PMCID: PMC6482462          DOI: 10.1016/j.bbadis.2017.12.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  5 in total

1.  Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway.

Authors:  Sally L Elshaer; Abdulrahman Alwhaibi; Riyaz Mohamed; Tahira Lemtalsi; Maha Coucha; Frank M Longo; Azza B El-Remessy
Journal:  Diabetologia       Date:  2019-05-09       Impact factor: 10.122

Review 2.  The innate immune system in diabetic retinopathy.

Authors:  Warren W Pan; Feng Lin; Patrice E Fort
Journal:  Prog Retin Eye Res       Date:  2021-01-08       Impact factor: 19.704

3.  Modulating Expression of Thioredoxin Interacting Protein (TXNIP) Prevents Secondary Damage and Preserves Visual Function in a Mouse Model of Ischemia/Reperfusion.

Authors:  Maha Coucha; Ahmed Y Shanab; Mohamed Sayed; Almira Vazdarjanova; Azza B El-Remessy
Journal:  Int J Mol Sci       Date:  2019-08-15       Impact factor: 5.923

4.  Modulation of p75NTR on Mesenchymal Stem Cells Increases Their Vascular Protection in Retinal Ischemia-Reperfusion Mouse Model.

Authors:  Sally L Elshaer; Hang-Soo Park; Laura Pearson; William D Hill; Frank M Longo; Azza B El-Remessy
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

Review 5.  Nerve Growth Factor and Pathogenesis of Leprosy: Review and Update.

Authors:  Tinara Leila de Souza Aarão; Jorge Rodrigues de Sousa; Aline Semblano Carreira Falcão; Luiz Fábio Magno Falcão; Juarez Antônio Simões Quaresma
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.